The short version of HPLC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
== Evidence == It has been demonstrated in animal experiments that there is an improvement in sorbitol levels and Na+/K+ ATPase activity leading to improved nerve conduction velocity. Diabetic rats treated with epalrestat showed improvement in morphological abnormalities of nerves. In a placebo controlled double blind trial of 196 patients, it was shown that Epalrestat in a dose of 150 mg/day improved the effects of diabetic neuropathy like upper limb spontaneous pain, motor nerve conduction velocity, thresholds of vibratory sensation and autonomic nerve function as compared to a placebo. These effects were significantly better in those with poorer control of diabetes. A systematic review and metaanalysis showed that based on the results of 10 articles, it can be concluded that Epalrestat has some benefit in the control of diabetic cardiovascular autonomic neuropathy but only in the early or mild cases. It also doesn't influence glycaemic control.
Special Police Units/Special operations units are organised and placed at the Municipal and Provincial level. In addition, the 1st and 2nd Mobile Corps maintain a total of 5 Special Operations Detachments. Municipal detachments each have their own Special Operations Company, which is typically placed under the municipal mobile battalion. Each provincial corps (Chinese: 总队; pinyin: Zǒngduì) establishes and maintains a special operations detachment as part of its own territorial organisation. The provincial special operations detachment of the Xinjiang Corps is the Mountain Eagle Commando Unit. In some provincial corps, the special operations unit is battalion or company sized and is placed under the mobile detachment. The Hebei Corps Mobile Detachment's 1st Special Operations Company is known as the "Sky Sword" unit (Chinese: 天剑突击队). It can trace its lineage back to the 7th Company, 3rd Battalion of the 28th Group Army's 84th Infantry Division's 251st Regiment which was involved in the Battle of Jinan and the Huaihai campaign. In its entire history, it was deployed to approximately 50 law enforcement/disaster relief operations, won gold or silver in 100+ competitions and was awarded first class meritorious service medals 1 time, 2nd class meritorious service medals 5 times and 3rd class meritorious service medals 12 times. The Shenzhen Detachment's Special Operations Company is known as the "Wild Wolf" unit (Chinese: 野狼特战队). It was founded in 2005 and given the name in 2008.
B&K Corporation Limited (Traditional Chinese: 青城新藥生物科技（青島）股份有限公司, SEHK: 2396) is a China-based biopharmaceutical company founded in 2012 and headquartered in Qingdao. The company is engaged in the research, development and commercialisation of protein-based therapeutics, with a primary focus on platelet-derived growth factor (PDGF) drugs for wound healing indications. The joint sponsors of the offering were Huatai Financial Holdings (Hong Kong) and CITIC Securities (Hong Kong).
Sources: en.wikipedia.org
=== Morphology === Vernix is composed of mobile corneocytes embedded in an amorphous lipid matrix. Precise biological mechanisms leading to its formation are poorly understood. The cells are polygonal or ovoid in shape, malleable, and lack nuclei; typical thickness is 1-2 μm. Nuclear ghosts are frequently observed and Acid Phosphatase Activity is nonuniform. Keratin filaments build a scaffold like structure which form a water-storage area. As opposed to stratum corneum, the vernix corneocytes lack desmosomal attachment and the lipid layer is more disordered.
==== Shocks ==== Shocks are short-term deviations from long-term trends that have substantial negative effects on a system, people's state of well-being, assets, livelihoods, safety and ability to withstand future shocks. Shocks impacting on agrifood systems may be covariate (an event that directly affects groups of households, communities, regions or even entire countries) or idiosyncratic (an event that affects individuals or households) and include disasters, extreme climate events, biological and technological events, surges in plant and animal diseases and pests, socio-economic crises and conflicts.
Defective interfering (DI) genomes or defective viral genomes (DVGs) or defective interfering particles (DIPs) are replication defective viral RNA products generated during viral infections by many types of viruses, including SeV. It has been experimentally established that DI genomes can be readily produced by viral infection at high multiplicity. A single amino acid substitution in a nucleoprotein (NP) causes an increased production rate of DI genomes in the SeV Cantell strain, which is known for its particularly strong induction of interferon beta (IFN-β) during viral infection. It has been shown that DI are responsible for this strong IFN-β induction. Other genomic change such as loss of the Sendai virus C-protein has also been demonstrated to cause accumulation of DI genomes.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.